Diabetes: pericyte-orchestrated islet inflammation as a driver of beta-cell failure

Informacje na temat projektu

PIIN_T2D

Identyfikator umowy o grant: 101088870

DOI

10.3030/101088870

Data podpisania przez KE 9 Maja 2023

Data rozpoczęcia 1 Lipca 2023

Data zakończenia 30 Czerwca 2028

Finansowanie w ramach

• European Research Council (ERC)

Koszt całkowity

€ 2 000 000,00

Wkład UE

€ 2 000 000,00

Koordynowany przez

TEL AVIV UNIVERSITY
Israel

Periodic Reporting for period 1 - PIIN_T2D (Diabetes: pericyte-orchestrated islet inflammation as a driver of beta-cell failure)

Okres sprawozdawczy: 2023-07-01 do 2025-12-31

Podsumowanie kontekstu i ogólnych celów projektu

Type 2 diabetes (T2D) affects hundreds of millions of people worldwide. It develops when the pancreas cannot produce enough insulin or when the body stops responding to insulin effectively. A major contributor to this condition is the gradual failure of insulin-producing cells, known as beta cells, in the pancreas. While the immune system is typically associated with inflammation and disease, it also plays important roles in supporting healthy tissue function, including in the pancreas.

This ERC-funded project explores how a specialized type of blood vessel cell, called a pericyte, influences the immune environment in the pancreas to support beta cell health. The goal is to understand how pericytes communicate with immune cells under normal conditions, and how this process might become disrupted in diabetes.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

To investigate this, we created genetically engineered mouse models that allow us to selectively switch off specific immune signaling pathways in pericytes. These models enabled us to study how pericytes affect the behavior of nearby immune cells and how these interactions, in turn, impact the function of insulin-producing beta cells.

We discovered that pericytes help maintain a balanced immune environment by producing signaling molecules that guide immune cell activity. One of these molecules, CXCL1, prompts immune cells called macrophages to release IL-1beta, a signal that, under healthy conditions, helps maintain the identity and function of beta cells. Additional cytokines produced by pericytes also help attract and support a specific group of macrophages that contribute to beta cell health. When these pericyte-derived signals were disrupted, the balance of immune activity in the pancreas shifted, leading to impaired beta cell function and a reduced ability to regulate blood sugar.

These findings were published in The Journal of Clinical Investigation (2024) and presented at leading international conferences.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

These findings challenge the idea that inflammation in the pancreas is always harmful. Instead, our work reveals that a certain level of controlled immune activity is essential for maintaining healthy insulin production. We refer to this process as pericyte-orchestrated islet inflammation (PIIN).

This is the first time pericytes have been shown to actively control immune signals that are critical for pancreatic function. The concept of PIIN provides a new framework for understanding immune–endocrine communication and opens the door to novel therapies that aim to restore healthy immune signaling in people at risk of developing diabetes.

In addition to these scientific advances, we developed new genetic models that allowed us to selectively study the role of pericytes in immune signaling in vivo. These tools have been instrumental in uncovering how pericytes regulate the local immune environment and support beta cell function, and they continue to support ongoing experiments within the project.

In summary, this project sheds light on the cooperation between blood vessels, immune cells, and insulin-producing cells in the pancreas. By understanding how this communication works in health, we hope to find new ways to prevent or treat diabetes.